TriangleDISEASE & TREATMENT SETTING
Laryngeal Cancer
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Laryngeal Cancer
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- unresolved
- derivation note
- Derived from NCI topic(s): Laryngeal Cancer. Strongest NCIt resolution: ambiguous. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
- source wording
- Source null
6 more-specific settings
Study evidence for this setting
Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase II Trial Evaluating Elimination of Radiation Therapy
Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)
Assessing the da Vinci® Robotic Surgical System for Surgery of the Upper Aerodigestive Tract
F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients
Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
Clinical Feasibility of New Tracheoesophageal Puncture Set
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-laryngeal-cancer
- binding id
- ncit-C4855
- source collection
- ncit-concept
- source key
- C4855
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-laryngeal-cancer
- binding id
- ncit-C7484
- source collection
- ncit-concept
- source key
- C7484
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice